Sun Pharmaceutical Industries, Inc. received approval in 2007 for the vaginal formulation of Progesterone (NDA 022057), a move that likely expanded the company’s portfolio in the women's healthcare sector while focusing on patient-friendly delivery methods for high-demand therapies.